Florida Medicaid does not cover GLP-1 medications like Wegovy, Zepbound, Ozempic, or Mounjaro when they are prescribed for weight loss. It does cover them when the same drugs are prescribed for a condition federal law requires Medicaid to treat, most commonly type 2 diabetes. So the answer to whether Medicaid covers GLP-1 drugs in Florida depends entirely on what the prescription is written for.
What Florida Medicaid Will and Won’t Pay For
Florida’s Agency for Health Care Administration applies a blanket exclusion for “agents used for anorexia, weight loss, or weight gain.”1George Washington University. Medicaid Obesity Coverage – Florida Newer brand-name GLP-1s such as Wegovy and Zepbound are “not routinely covered for weight loss indication” and are “excluded for weight loss” under the program. Older, cheaper weight-loss drugs such as phentermine and orlistat may be covered in some circumstances.2The Actuary Magazine. GLP-1 Medications
The picture flips when the diagnosis changes. Under the federal Medicaid Drug Rebate Program, state Medicaid programs must cover nearly all FDA-approved drugs for their approved medical uses. That means a GLP-1 prescribed for type 2 diabetes has to be covered. The same obligation attaches to Wegovy prescribed for cardiovascular disease risk reduction and to Zepbound prescribed for moderate to severe obstructive sleep apnea in adults with obesity, both of which carry FDA approval for those indications.3KFF. Medicaid Coverage of and Spending on GLP-1s
Specifics for any given plan sit on Florida’s Preferred Drug List, which AHCA maintains and updates quarterly. That document tells you which diabetes medications are preferred and what prior authorization steps your plan will require.4Florida Agency for Health Care Administration. Florida Medicaid Preferred Drug List
Why the Weight-Loss Exclusion Exists
Federal law (42 U.S.C. § 1396r-8) lets states exclude “drugs used for weight loss” from Medicaid, and Florida is one of 38 states (counting Washington, D.C.) that uses the exclusion.5National Conference of State Legislatures. GLP-1s: Cost, Coverage, State Policy Trends As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity, and the trend has moved toward dropping coverage, not adding it. Between October 2025 and January 2026, California, New Hampshire, Pennsylvania, and South Carolina all eliminated coverage, citing budget pressure.6Stateline. More States Consider Dropping GLP-1 Weight Loss Drugs From Medicaid
Options if You’re on Florida Medicaid and Want a GLP-1
The exclusion is narrow in one important way: it applies to the indication on the prescription, not to the drug itself. A few routes may be open to you.
- Coverage based on another diagnosis. If your prescriber determines a GLP-1 is medically necessary for type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea with obesity, Medicaid is required to cover it. Weight change that follows is a side effect of covered therapy, not a separate benefit you have to qualify for.
- Enrollees under 21. Medicaid’s Early and Periodic Screening, Diagnostic and Treatment benefit requires states to cover treatments deemed medically necessary for children, which could include obesity medications; Wegovy is FDA-approved for adolescents 12 and older with obesity. There is no publicly available evidence that Florida has actually approved GLP-1s for pediatric obesity under this benefit, so expect to make the medical necessity case.7HelloKlarity. Self-Pay Options for Wegovy Without Insurance1George Washington University. Medicaid Obesity Coverage – Florida
- Older weight-loss medications. Phentermine, orlistat, and combination drugs like Qsymia and Contrave are cheaper and may have some Florida Medicaid coverage.
- Bariatric surgery. Florida Medicaid covers gastric bypass, gastric banding, and sleeve gastrectomy for adults 18 and older with a BMI of 40 or higher, or 35 or higher with a qualifying comorbidity. The approval process is long: it includes a primary care referral, a letter of medical necessity, a six-month physician-supervised weight loss program, nutritional counseling, a psychiatric evaluation, and cardiac clearance.1George Washington University. Medicaid Obesity Coverage – Florida8Sunshine Health. Bariatric Surgery Checklist9UF Health. Bariatric Surgery – Surgical Criteria
- Clinical trials. ClinicalTrials.gov lists research studies that may supply GLP-1 medication and monitoring at no cost.
One thing to rule out early: the manufacturer savings cards and copay programs Novo Nordisk and Eli Lilly advertise for Wegovy, Zepbound, and similar drugs generally cannot be used by anyone enrolled in a government health program, including Medicaid, because of federal anti-kickback rules.7HelloKlarity. Self-Pay Options for Wegovy Without Insurance Florida also runs a GLP-1 pilot through its state employee health plan, but that program is for state workers and is not available to Medicaid beneficiaries.10Obesity Action Coalition. Florida SEHP 2026
What Could Change the Answer
Two efforts to expand Florida Medicaid coverage for obesity drugs died in committee in June 2025: House Bill 713, filed by Representative Basabe,11Florida House of Representatives. HB 713 – Obesity Treatment and Diabetes Prevention12BillTrack50. FL S0648 – Diabetes Prevention and Obesity Treatment Act13Fierce Healthcare. Medicare Advantage Final Rule Excludes Anti-Obesity Drug Coverage Under Medicare Medicaid14Healio. CMS Decision to Remove Obesity Drug Coverage From 2026 Final Rule Disappoints Societies
The nearer-term development is the BALANCE Model, a voluntary CMS Innovation Center demonstration launched in December 2025 that negotiates lower GLP-1 prices with Novo Nordisk and Eli Lilly for participating state Medicaid programs. The Medicaid component opened May 1, 2026, with state applications accepted on a rolling basis through July 31, 2026.15Centers for Medicare & Medicaid Services. CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines, Promote Healthier Living16KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid Whether Florida will apply has not been publicly reported. Separately, Novo Nordisk announced in February 2026 that it would cut list prices on its GLP-1 medications to $675 per month starting in 2027,6Stateline. More States Consider Dropping GLP-1 Weight Loss Drugs From Medicaid which could change the cost calculation for holdout states, Florida included.
For now, the practical answer stays the same: if your prescription is for weight loss, Florida Medicaid will not pay. If it’s for a covered medical condition the same drug treats, it will. Talk with your prescriber about which indication fits your medical picture, and check your managed care plan’s current Preferred Drug List for prior authorization steps before you fill.